Angiotech addresses legal proceedings
18 Februar 2005 - 10:52PM
PR Newswire (US)
Angiotech addresses legal proceedings VANCOUVER, Feb. 18
/PRNewswire-FirstCall/ -- As previously announced on February 1st,
2005, Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) along with its corporate partner
Boston Scientific initiated legal proceedings in the Netherlands
against Conor Medsystems after the validity of one of Angiotech's
European patents (No. EP 0 706 376) was upheld by the European
Patent Office Opposition Division. Angiotech anticipates that Conor
Medsystems will, in response to those legal proceedings take
various defensive acts, including the present challenge in the
United Kingdom. As legal proceedings can historically be a
drawn-out process in multiple jurisdictions, Angiotech will pursue
and defend against, to the fullest, any and all actions of Conor
Medsystems respecting Angiotech's extensive patent portfolio and
pioneering technology. Vancouver-based Angiotech Pharmaceuticals,
Inc., a specialty pharmaceutical company focusing on drug-eluting
medical devices and biomaterials, is dedicated to enhancing the
performance of medical devices and biomaterials through the
innovative uses of pharmacotherapeutics. To find out more about
Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP),
please visit our website at http://www.angiotech.com/. Statements
contained herein that are not based on historical or current fact,
including without limitation statements containing the words
"anticipates," "believes," "may," "continue," "estimate,"
"expects," "may" and "will" and words of similar import, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Such factors include, among others, the following:
general economic and business conditions, both nationally and in
the regions in which the Company operates; technology changes;
competition; changes in business strategy or development plans; the
ability to attract and retain qualified personnel; existing
governmental regulations and changes in, or the failure to comply
with, governmental regulations; liability and other claims asserted
against the Company; and other factors referenced in the Company's
filings with the United States Securities and Exchange Commission
or the Canadian securities regulators. Given these uncertainties,
readers are cautioned not to place undue reliance on such
forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements. CONTACTS: Todd
Young, Angiotech Pharmaceuticals (Analysts & Investors) (604)
221-7676 ext 6933 Rui Avelar, Angiotech Pharmaceuticals, Inc.
(Analysts) (604) 221-7676 ext 6996 Eric Starkman, Starkman &
Associates (Media) (212) 252-8545 ext 12 DATASOURCE: Angiotech
Pharmaceuticals, Inc. CONTACT: Todd Young, Angiotech
Pharmaceuticals (Analysts & Investors), (604) 221-7676 ext
6933; Rui Avelar, Angiotech Pharmaceuticals, Inc. (Analysts), (604)
221-7676 ext 6996; Eric Starkman, Starkman & Associates
(Media), (212) 252-8545 ext 12
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Angiotech Pharmaceuticals (MM) News-Artikel